Last week Justice Edelman delivered judgment in the Federal Court, finding that Reckitt Benckiser (Australia)’s packaging and website descriptions of the Nurofen ‘Specific Pain Range’ constituted misleading or deceptive conduct under section 18 of the Australian Consumer Law (‘ACL’).
A Full Court of the Federal Court of Australia appeared to suggest that patent cases involving claimed inventions for computer implemented business methods can be determined using an established framework and such cases are no longer at the cutting edge of patentability – that mantle has been assumed by gene technology.
The Federal Court of Australia has found that Reckitt Benckiser engaged in misleading and deceptive conduct in the packaging and online information about a range of Nurofen products
The vocational education and training (VET) sector is under the spotlight for misleading conduct and false representations, as ACCC litigates to resolve